Lisata Therapeutics, Inc.

NasdaqCM:LSTA Stock Report

Market Cap: US$17.7m

Lisata Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of LSTA?
Owner TypeNumber of SharesOwnership Percentage
Institutions716,3678.52%
Individual Insiders1,496,26217.8%
General Public6,196,21573.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 26.31% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.1%
Erkki Ruoslahti
1,103,000US$2.3m-6.62%no data
3.15%
David Mazzo
264,690US$555.8k153%no data
2.58%
BML Capital Management, LLC
216,853US$455.4k-23.8%0.4%
2.22%
The Vanguard Group, Inc.
186,366US$391.4k0%no data
1.2%
Renaissance Technologies LLC
101,322US$212.8k-2.22%no data
0.95%
Kristen Buck
79,794US$167.6k27.3%no data
0.66%
Geode Capital Management, LLC
55,895US$117.4k0.38%no data
0.65%
BlackRock, Inc.
54,857US$115.2k-2.06%no data
0.3%
Dimensional Fund Advisors LP
25,226US$53.0k45.5%no data
0.29%
Tariq Imam
24,579US$51.6k0%no data
0.28%
James Nisco
23,491US$49.3k576%no data
0.28%
Citadel Advisors LLC
23,273US$48.9k0%no data
0.17%
State Street Global Advisors, Inc.
14,348US$30.1k0%no data
0.14%
Cook Wealth, LLC
12,175US$25.6k0%0.01%
0.12%
Merrill Lynch & Co. Inc., Banking Investments
10,353US$21.7k7.2%no data
0.12%
HighTower Advisors, LLC
10,042US$21.1k0%no data
0.024%
Founders Capital Management Inc
2,000US$4.2k0%no data
0.023%
Tower Research Capital Europe Limited
1,915US$4.0k25.5%no data
0.017%
Morgan Stanley, Investment Banking and Brokerage Investments
1,458US$3.1k0%no data
0.0051%
Steven Klosk
432US$907.70%no data
0.0033%
Gregory Brown
276US$579.20%no data
0.0017%
SBI Holdings Inc., Asset Management Arm
140US$293.1-74.1%no data
0.00068%
Bank of America Corporation, Asset Management Arm
57US$120.10%no data
0.00046%
City National Rochdale, LLC
39US$81.20%no data
0.00018%
JPMorgan Chase & Co, Brokerage and Securities Investments
15US$31.80%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 22:15
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lisata Therapeutics, Inc. is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jan WaldBenchmark Company
Kumaraguru RajaBrookline Capital Markets
Brian Kemp DolliverBrookline Capital Markets